Videoconference and publication of the 2021-2022 Half-Year Results, on December 8, 2021
December 2, 2021
December 2, 2021
MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)
December 1, 2021
December 1, 2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability
November 1, 2021
November 1, 2021
MedinCell announces participation in the Jefferies London Healthcare Conference 2021
